

JG13 Rec'd PCT/PTO 17 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Duncan *et al.*

Art Unit: Not Yet Assigned

Application No. Not Yet Assigned

CERTIFICATE OF MAILING

Filed: Herewith

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on December 17, 2001 as U.S. Express Mail in an envelope addressed to: BOX PCT, Commissioner for Patents, Washington, D.C. 20231.

For: BIOLOGICALLY ACTIVE MATERIALS

Examiner: Not Yet Assigned

William D. Noonan
William D. Noonan, M.D., J.D.
Attorney for Applicant

Date: December 17, 2001

BOX PCT
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced application, please amend the application as follows:

In the Specification:

On page 1, line 2, please insert the following:

PRIORITY CLAIM

This is a U.S. National Stage § 371 of PCT/GB00/02216, filed June 19, 2000, which was published in English under PCT Article 21(2), which claims the benefit of U.K. Application GB9914187.1, filed June 18, 1999, and U.K. Application GB9930252.3, filed December 22, 1999.

In the Claims:

Please cancel pending claims 14 and 15 without prejudice. Please amend pending claims 2-13 and 16-23 as follows:

1. (Reiterated) A polymer drug conjugate comprising:
at least one anti-cancer agent; and